FIGURE 7

Cisplatin- and TRAIL-induced cellular changes in DR5-AS knockdown HeLa cells. (A) Proliferation rate of cisplatin-treated HeLa cells transfected with DR5-AS GapmeR. HeLa cells were transfected with DR5-AS GapmeR-1 for 72 h and then treated with cisplatin for additional 16 h. Proliferation rate of cells was measured by WST-1 assay. “Only cell” (no transfection), “transfection reagent” (cells transfected with transfection reagent only), and negative GapmeR were used as controls. (B) qPCR analyses of cell cycle-associated genes in cisplatin-treated HeLa cells. HeLa cells were treated with 80 μM cisplatin for 16 h and qPCR analyses were carried out with total RNAs isolated from control (0.1% DMSO) and cisplatin-treated cells. (C) Dose response of HeLa cells treated with TRAIL for 3 h treatment. (D) Apoptosis rate of HeLa cells after TRAIL treatment. HeLa cells were treated with 200 ng/ml TRAIL for 3 h. The rate of apoptosis was measured by flow cytometry following Annexin V/7AAD staining. ns, non-significant, p > 0.05, ^∗p ≤ 0.05, ^∗∗p ≤ 0.01, ^∗∗∗p ≤ 0.001, and ^****p ≤ 0.0001.